The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity

Pharmacology and Therapeutics

Volumn 68, Issue 3, 1995, Pages 385-424

  Park, B Kevin ^a   Pirmohamed, Munir ^a   Kitteringham, Neil R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

chemically reactive metabolite; Cytochrome P450; drug metabolism; drug toxicity; extrahepatic; interindividual variation

Indexed keywords

CYTOCHROME P450; DAPSONE; PARACETAMOL; TACRINE; UNINDEXED DRUG; VALPROIC ACID;

BLADDER DISEASE; CARCINOGENICITY; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; GENITAL SYSTEM DISEASE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ACETAMINOPHEN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; HEMATOLOGIC DISEASES; HUMANS; LIVER DISEASES; LUNG DISEASES; NERVOUS SYSTEM DISEASES; PHARMACEUTICAL PREPARATIONS; TACRINE; VALPROIC ACID;

EID: 0029588524     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(95)02013-6     Document Type: Review

References (369)

1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture
2. Genes for cytochrome-P-450 and their regulation
3. Role of ethanol-inducible cytochrome P-450 (P-450IIE1) in catalysis of the free radical activation of aliphatic alcohols
4. Effects of cytokines on the liver
5. Carcinoma of the bladder complicating cyclophosphamide therapy
6. Zonation of acetaminophen metabolism and cytochrome-P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes
7. cDNA-directed expression of rat P450-IIA1 and P450-IIA2—catalytic activities toward steroids and xenobiotics and comparison with the enzymes purified from liver
8. 5 of 12 forms of vaccinia virus-expressed human hepatic cytochrome-P450 metabolically activate aflatoxin-B1
9. Vulnerability to alcoholic liver disease
10. Ketoconazole and fluconazole drug interactions
11. Interaction of citrus juices with felodipine and nifedipine
12. Grapefruit juice felodipine interaction—mechanism, predictability, and effect of naringin
13. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics
14. Grapefruit juice and drugs: how significant is the interaction?
15. Marked effects of both erythromycin and grapefruit juice on felodipine pharmacokinetics
16. Oxidative and conjugative metabolism of diethylstilbestrol by rabbit preimplantation embryos
17. Autoantibodies against cytochrome P-450 in drug-induced autoimmune hepatitis
18. Human drug metabolism in vitro
19. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug
20. c
21. Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor: a comparison with lymphotoxin and interferon
22. Membrane topology of the mammalian P450 cytochromes
23. Membrane topology of liver microsomal cytochrome P450 2B4 determined via monoclonal antibodies directed to the halt-transfer system
24. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P450IA2, a specific marker of dihydralazine-induced hepatitis
25. Evidence for the Clara cell as a site for cytochrome P450-dependent mixed-function oxidase activity in the lung
26. Biochemical mechanisms in chemical-induced lung injury: roles of metabolic activation
27. Liver failure induced by paracetamol
28. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure
29. Adrenal autoantibodies bind to adrenal subcellular fractions enriched in cytochrome c reductase and 5′-nucleotidase
30. Lamotrigine
31. Adverse drug interactions
32. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
33. Membrane topology of mammalian cytochromes P-450 from liver endoplasmic reticulum
34. Stereoselectivity of naphthalene epoxidation by mouse, rat, and hamster pulmonary, hepatic, and renal microsomal enzymes
35. Relationship of cytochrome P450 activity to Clara cell cytotoxicity. II. Comparison of stereoselectivity of naphthalene epoxidation in lung and nasal mucosa of mouse, hamster, rat and rhesus monkey
36. Prenatal prediction of risk of the fetal hydantoin syndrome
37. Cimetidine as adjunctive treatment for acetaminophen overdose
38. Aetiology of Parkinson's disease
39. Lung cancer and the debrisoquine metabolic phenotype
40. Drug-drug interactions of fluoxetine with tricyclics
41. Altered theophylline pharmacokinetics during acute respiratory viral illness
42. Block of delayed rectifier potassium current, Ik, by terfenadine in cat ventricular myocytes
43. Use of cryopreserved animal and human hepatocytes for cytotoxicity studies
44. Viability and function in primary culture of adult hepatocytes from various animal species and human-beings after cryopreservation
45. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
46. Characterization of hepatic-microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1236-tetrahydropyridine in mice
47. Stereoselective interaction between the R enantiomer of warfarin and cimetidine
48. Toxic nephropathy after low-dose methoxyflurane anesthesia: drug interaction with secobarbital
49. Fluoxetine drug-drug interactions. 2
50. Detection of antibodies against proteins modified by hydroxyethyl free-radicals in patients with alcoholic cirrhosis
51. Urinary metabolites of halothane in man
52. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man
53. Classification of allergic reactions responsible for clinical hypersensitivity and disease
54. Cutaneous T-cell recruitment in toxic epidermal necrolysis
55. Cyclophosphamide cystitis—identification of acrolein as the causative agent
56. A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing
57. Metabolic polymorphisms
58. Medical hypothesis—xenoestrogens as preventable causes of breast-cancer
59. Hepatic disorders
60. Genetic predisposition to alcoholic liver disease
61. Determination of membrane topology of the phenobarbital-inducible rat liver cytochrome P450 isozyme PB-4 using site-specific antibodies
62. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome
63. Xenobiotic metabolism by isolated pulmonary cells
64. Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effects of glutathione and vitamin E
65. The effect of fluvoxamine at steady-state on the pharmacokinetics of theophylline after a single dose in healthy male volunteers
66. Enzymatic defences of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin
67. Valproic acid hepatic fatalities: a retrospective review
68. Valproic acid hepatic fatalities. II. US experience since 1984
69. Trough concentrations of cyclosporine in blood following administration with grapefruit juice
70. Is enflurane hepatotoxic?
71. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects
72. Drug-related hospital admissions
73. Effect of hepatic disease on terfenadine and terfenadine metabolite pharmacokinetics
74. In vitro production of IL-1-beta, IL-1-alpha, TNF and IL-2 in healthy-subjects—distribution, effect of cyclooxygenase inhibition and evidence of independent generegulation
75. Rotation and interaction with epoxide hydrase of cytochrome P-450 in proteoliposomes
76. The incidence of bladder cancer after cyclophosphamide therapy
77. A controlled trial of tacrine in Alzheimer's disease
78. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis
79. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients
80. Clinical experience with and side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study
81. Cyclophosphamide toxicity. Characterising and avoiding the problem
82. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine
83. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man
84. Quinolone antibacterial agents-relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2
85. Role of human microsomal and human complementary DNA-expressed cytochrome-P4501A2 and cytochrome-P4503A4 in the bioactivation of aflatoxin-B(1)
86. Pharmacokinetics and biotransformation studies of terfenadine in man
87. Pre-translational regulation of cytochrome P450 genes is responsible for disease specific changes of individual P450 enzymes among patients with cirrhosis
88. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease
89. Reye-like syndrome associated with valproic acid therapy
90. Comparison of O6-alkylguanine DNA transferase activity based on cellular DNA content in human, rat and mouse tissues
91. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in human brain
92. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity
93. Intra- and extra-cellular formation of metabolites from chemically reactive species
94. Haemolysis by diphenylsulfones: comparative effects of DDS and hydroxylarnine-DDS
95. Production of the features of Reyes syndrome in rats with 4-pentanoic acid
96. The molecular biology of cytochrome P450s
97. Human cytochromes P450: problems and prospects
98. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins
99. Molecular genetics of the debrisoquin-sparteine polymorphism
100. Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism
101. 2-Year carcinogenicity study of tamoxifen in Alderley-Park Wistar-derived rats
102. Fluoxetine impairs clearance of alprazolam but not of clonazepam
103. Increased carbamazepine plasma-concentrations after fluoxetine coadministration
104. Rheumatoid arthritis, the effects of treatment with dapsone on haemoglobin
105. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody
106. Reactions and significance of P450 enzymes
107. Characterization of human cytochrome P450 enzymes
108. Metabolic activation of carcinogens
109. Catalytic selectivity of human cytochrome-P450 enzymes — relevance to drug-metabolism and toxicity
110. Human cytochrome P450 enzymes and chemical carcinogenesis
111. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
112. Mechanisms of halothane toxicity: novel insights
113. Induction of covalent DNA adducts in rodents by tamoxifen
114. Teratogen update fetal hydantoin effects
115. The fetal hydantoin syndrome
116. Cimetidine does not increase the anticoagulant effect of phenprocoumon
117. Chemical and physical carcinogenesis: advances and perspectives for the 1990s
118. Genetic polymorphisms in the 5′-flanking region change transcriptiohal regulation of the human cytochrome P450IIE1 gene
119. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes
120. Characterization of xenobiotic metabolizing cytochrome P450 enzymes in human and rat breast tissue
121. Evidence that the androgen receptor mediates sexual differentiation of mouse renal cytochrome P450 expression
122. Testosterone-mediated regulation of cytochrome P450 gene expression will explain sex differences in response to nephrotoxins and carcinogens
123. Role of covalent and noncovalent interactions in cell toxicity: effects in proteins
124. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis
125. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
126. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine
127. The pharmacokinetics and cardiac consequences of the terfenadine-ketoconazole interaction
128. Liver-disease induced by perhexilene maleate
129. Paroxetine pimozide drug-interaction
130. Is environmental carcinogenesis modulated by host polymorphism?
131. Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane
132. 1,1,1-Trichloropropene-2,3-oxide: an alternate mechanism for its inhibition of cytochrome P-450
133. Antioxidant response element
134. Toxic reaction following the combined administration of fluoxetine and phenytoin— 2 case-reports
135. Arene oxides: a new aspect of drug metabolism
136. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine—evidence from a therapeutic drug-monitoring service
137. Possible interaction of sertraline with carbamazepine
138. Inherited amplification of an active gene in the cytochrome-P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
139. Urinary bladder fibrosis and telengiectasia associated with longterm cyclophosphamide therapy
140. Biotransformation in liver disease
141. Evaluation of the cytotoxicity of 10 chemicals on human cultured-hepatocytes—predictability of human toxicity and comparison with rodent cell-culture systems
142. Bioactivation in chemical teratogenesis
143. Xenobioticbiotransformation/bioactivation in organogenesisstage conceptal issues: implications for embryotoxicity and teratogenesis
144. Cimetidine and paracetamol hepatotoxicity
145. Metabolism and cytotoxicity of naphthalene oxide in the isolated perfused mouse lung
146. Teratogenicity of antiepileptic drugs: analysis of possible risk factors
147. The in vitro metabolism of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) by hepatic microsomal cytochrome P-450
148. Identification and characterisation of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans
149. Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose
150. Teratogenicity of anticonvulsant drugs. I —review of the literature
151. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane
152. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver-microsomes
153. Clinical enflurane metabolism by cytochrome P4502E1
154. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants
155. Acute renal failure due to acetaminophen ingestion without concurrent hepatotoxicity
156. Extrahepatic metabolism of drugs in humans
157. Malignant renal tumours in male hamsters (Cricetus aurus) treated with estrogen
158. The fate of antigens
159. Differential inhibition of individual human liver cytochromes-P-450 by cimetidine
160. Aldose reductase-catalysed reduction of acrolein: implications for cyclophosphamide toxicity
161. Cytochromes P450: their active-site structure and mechanism of oxidation
162. Altered theophylline clearance during an influenza-B outbreak
163. Theophylline toxicity and viral-infections-reply
164. Fetal drug metabolism and its possible clinical implications
165. P53 mutations are absent from carcinogen-induced mouse-liver tumors but occur in cell-lines established from these tumors
166. MPTP and Parkinson's disease
167. Effects of erythromycin on hepatic drug metabolising enzymes in humans
168. Formation of inactive cytochrome P450 Fe (II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats
169. Autoantibodies in alcoholic liver disease
170. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity
171. Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia
172. Toxicity of paracetamol and cyclophosphamide in monolayer-cultures of rat and human hepatocytes
173. Dapsone, trimethoprim and sulphamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS)
174. Human anti-cytochrome-P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions
175. Characterization of the human anti-cytochrome P450 antibody response in hypersensitivity reactions to aromatic anticonvulsants
176. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam
177. Effects of polytherapy with phenytoin, carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid
178. Trail of ironies to Parkinson's disease
179. Estrogen carcinogenesis in hamster tissues—a critical-review
180. Biochemical and molecular basis of alcohol induced injury to liver and other tissues
181. Metabolism and pharmacokinetics of acetaminophen in a severely poisoned young child
182. 2-Fluorooestradiol: separation of estrogenicity from carcinogenicity
183. DNA adduct formation in liver and kidney of male Syrian-hamsters treated with estrogen and or alpha-naphthoflavone
184. A comparativestudy of tamoxifen metabolism in female rat, mouse and human liver-microsomes
185. Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis
186. Teratogenecity of anti-epileptic drug combinations with special emphasis on epoxidation (of carbamazepine)
187. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies
188. Immunology and the skin. Current concepts
189. Torsades de pointes complicating treatment with terfenadine
190. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes
191. Species variation in the bioactivation of tacrine by hepatic microsomes
192. A comparative study of biliary and urinary 2-hydroxylated metabolites of [6,7-3H]17α-ethynylestradiol in women
193. The biliary and urinary metabolites of 3H-17α-ethinyloestradiol in women
194. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation
195. Cytochrome P450 enzymes as human autoantigens
196. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a Cytochrome P-450 monooxygenase
197. Thiophene S-oxides as new reactive metabolites: formation by cytochrome P450 dependent oxidation and reaction with nucleophiles
198. The MPTP story: MAO activates tetrahydropyridine derivatives ot toxins causing Parkinsonism
199. Parkinson's disease
200. Carcinogenic properties of pharmaceutical agents evaluated in the IARC monographs program
201. An interaction between carbamazepine and fluvoxamine
202. Torsades de pointes occurring in association with terfenadine use
203. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture
204. Renal toxicity of anaesthetics with specific reference to the nephrotoxicity of methoxyflurane
205. Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation
206. Methoxyflurane metabolism and renal disfunction
207. Renal effects and metabolism of isoflurane in man
208. Inorganic fluoride nephrotoxicity: prolonged enflurane and halothane anaesthesia in volunteers
209. Cytokines and alcoholic liver disease
210. Cytochrome P450 expression in human hepatic disease
211. Clinical pharmacokinetics in patients with liver-disease
212. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix
213. Pharmacogenetics—the slow, the rapid, and the ultrarapid
214. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette-smoking
215. Selective serotonin reuptake inhibitors—adverse-effects, toxicity and interactions
216. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CDS-positive T cells
217. 2 shows stable interindividual differences
218. Torsades de pointes occurring in association with terfenadine use
219. Ethanol-derived immunoreactive species formed by free-radical mechanisms
220. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans?
221. Impaired oxidation of debrisoquine in patients with perhexilene liver injury
222. The metabolism of aflatoxin-B1 by human-liver
223. Amplification of an esterase gene is responsible for insecticide resistance in a California culex mosquito
224. Environmental factors affecting drug metabolism
225. Cutaneous cytochrome P-450
226. The immunohistochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450
227. Occurrence of beta-hexachlorocyclohexane in breast cancer patients
228. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system
229. Summary of the National Halothane Study
230. The hepatic and renal mechanisms of drug interactions with cimetidine
231. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature
232. The P450 superfamily—update on new sequences, gene-mapping, accession numbers, early trivial names of enzymes, and nomenclature
233. Molecular mechanisms of the hepatotoxicity caused by acetaminophen
234. Halothane hepatitis: a model of immune mediated drug hepatotoxicity
235. Antibodies against acetaldehyde-modified protein epitopes in human alcoholics
236. Immunohistochemical demonstration of acetaldehyde-modified epitopes in human liver after alcohol consumption
237. An o-quinone form of estrogen produces free-radicals in human breast-cancer cells—correlation with DNA-damage
238. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease
239. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds
240. Rotation and membrane topology of genetically expressed methylcholanthrene-inducible cytochrome P-4501A1 lacking the N-terminal hydrophobic segment in yeast microsomes
241. Depression of drug-metabolizing activity in the human liver by interferon-alpha
242. Depression of drug-metabolizing activity in the human liver by interferon-beta
243. Autoimmunity
244. Metabolic basis of adverse drug reactions
245. Relevance of and means of assessing induction and inhibition of drug metabolism in man
246. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications
247. Drug-protein conjugation and its immunological consequences
248. Drug disposition and drug hypersensitivity
249. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors
250. Bioactivation and bioinactivation of drugs and drug metabolites: relevance to adverse drug reactions
251. Metabolic activation of carcinogens and toxic chemicals
252. Acute and chronic drug-induced hepatitis
253. Cyclophosphamide and urinary bladder toxicity
254. Psychotropic-drugs, aging and community care
255. Enzyme inhibition mediated toxic effects of drugs
256. Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine
257. Investigation into the formation of cytotoxic, protein reactive and stable metabolites from carbamazepine in vitro
258. The role of active metabolites in drug toxicity
259. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians
260. Relationship of cytochrome P-450 to Clara cell cytotoxicity. I. Histopathologic comparison of the respiratory tract of mice, rats and hamsters after parenteral administration of naphthalene
261. Immunologic and metabolic basis of drug hypersensitivities
262. Neoantigens associated with halothane hepatitis
263. Intracellular glutathione in human hepatocytes incubated with S-adenosyl-L-methionine and GSH-depleting drugs
264. Metabolic disposition of the cognition activator in man: identification of phenol glucuronide metabolites in urine
265. Cytochrome P-450
266. Paracetamol overdosage. Pharmacological considerations and clinical management
267. Paracetamol-induced acute renal failure
268. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
269. Current knowledge of mechanisms of carcinogenicity: genotoxins vs. non-genotoxins
270. Bioactivation of aflatoxin-B1 by human liver-microsomes—role of cytochrome-P450 IIIA enzymes
271. The endo-8,9-epoxide of aflatoxin-B1—a new metabolite
272. Glutathione conjugation of aflatoxin-B1 exo-epoxides and endo-epoxides by rat and human glutathione S-transferases
273. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver-microsomes-potent inhibition by fluvoxamine
274. Acetaminophen activation by human liver cytochromes P-450IIE1 and P-450IA2
275. Clinical features and management of severe dermatological reactions to drugs
276. Pathogenesis of adverse drug reactions
277. Halothane biotransformation in man: a quantitative study
278. Regulation of hepatic cytochrome-P-450 during infectious-disease
279. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates
280. Cytochrome P450-catalyzed formation of VPA, a toxic metabolite of valproic acid
281. Hydroxylation of warfarin by human cDNA-expressed cytochrome-P-450—a role for P-4502C9 in the etiology of (S)-warfarin drug-interactions
282. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy
283. Electron transfer in P450 mechanisms. Microsomal metabolism of cyclopropylbenzene and p-cyclopropylanisole
284. Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues
285. Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognize rodent CYP3A proteins and a similarly regulated human P450 enzyme(s)
286. Renal tubular site of action of fluoride in Fischer 344 rats
287. Severe adverse cutaneous reactions to drugs
288. Kinetics of drug-drug interactions
289. Autoimmune reactions induced by procainamide and hydralazine
290. The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse
291. Effect of renal disease on terfenadine metabolite pharmacokinetics
292. Toxicity following methoxyflurane anaesthesia. IV. The role of obesity and the effect of low dose anesthesia on fluoride metabolism and renal function
293. Fatal liver failure in 16 children with valproate therapy
294. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure
295. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer
296. Lack of cytochrorme P450 2D6 (CYP2D6) deficiency phenotype in a cocaine dependent population
297. Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism
298. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy
299. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment
300. Ketoconazole: a potent inhibitor of cytochrome P-450 dependent drug metabolism in rat liver
301. Intracellular-localization of ethanol-inducible P450IIE1 in rat-liver-an immunoelectron microscopic study
302. Human drug metabolism in vivo
303. Debrisoquine hydroxylation gene polymorphism and susceptibility to Parkinson's disease
304. Lymphocyte transformation and alcohol liver injury
305. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes
306. Determination of human hepatic cytochrome P450 1A2 activity in vitro—use of tacrine as an isoenzyme specific probe
307. Toxic interaction between fluvoxamine and sustained-release theophylline in an 11-year-old boy
308. Predisposition to phenytoin hepatotoxicity assessed in vitro
309. Interaction between fluvoxamine and imipramine desipramine in 4 patients
310. Possible association of CYP2D6 genotype with oral opiate dependence
311. Catechol oestrogens as mediators of carcinogenesis: correlation of aromatic hydroxylation of oestradiol and its fluorinated analogs with tumor induction in Syrian hamsters
312. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis
313. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients
314. Genetic predisposition to phenytoin-induced birth defects
315. Role of brain cytochrome-P450 in regulation of the level of anesthetic steroids in the brain
316. Cytochrome P450s of the 4A subfamily in the brain
317. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s
318. Potential terfenadine-fluoxetine interaction
319. UDP-glucuronyl transferases: a family of detoxifying enzymes
320. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4
321. Drug hepatotoxicity
322. The use of a three compartment in vitro model to investigate the role of hepatic drug metabolism in drug-induced blood dyscrasias
323. Investigation of dapsone-induced methaemoglobinaemia in vitro effect of enzyme inhibition
324. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system
325. The effect of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes
326. An investigation of the formation of cytotoxic, genotoxic, protein-reactive and stable metabolites from naphthalene by human liver-microsomes
327. Renal failure following methoxyflurane analgesia
328. Metabolic-fate of phenprocoumon in humans
329. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man
330. The intralobular distribution of ethanol-inducible-P450IIE1 in rat and human-liver
331. Clinical implications of genetic polymorphism in drug metabolism
332. Immune responses to acetaldehyde-protein adducts: role in alcoholic liver disease
333. Neuronal cytochrome P450IID1 (deobrisoquine/sparteine-type): potent inhibition of activity by (−)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6
334. Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes
335. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions
336. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions
337. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells
338. Antigen processing and presentation
339. Risk of endometrial cancer after tamoxifen treatment of breast-cancer
340. Immunohistochemical detection of cytochrome P450 isoenzymes in cultured human epidermal cells
341. On the mechanism of action of cytochrome P450: evaluation of hydrogen abstraction in oxygen-dependent alcohol oxidation
342. Type II autoimmune hepatitis: the conundrum of cytochrome P450 IID6
343. Microsomal cytochrome P450: substrate binding, membrane interactions and topology
344. Immunopathology of toxic epidermal necrolysis
345. Interaction of metoprolol and fluoxetine
346. Brain cytochrome P450
347. Antimicrosomal anitbodies: what are they telling us?
348. Interferon inhibits hepatic-clearance of theophylline by a non competitive mechanism
349. Inhibition of theophylline metabolism by interferon
350. Interferon inhibits hepatic theophylline clearance
351. Evaluation of the generation of genotoxic and cytotoxic metabolites of benzo[a]pyrene, aflatoxin B1, naphthalene and tamoxifen using human liver microsomes and human lymphocytes
352. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type 1 and Addison's disease
353. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals
354. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility
355. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations: species differences
356. Fluoxetine-warfarin interaction
357. Antiarrhythmic drugs
358. Antibodies against acetaldehyde-modified epitopes: presence in alcoholic, non-alcoholic liver disease and control subjects
359. Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes
360. Renal impairment with chronic hydrocarbon exposure
361. Effect of grapefruit juice on blood cyclosporin concentration
362. Autoimmunity and alcoholic liver disease
363. Dermatitis herpetiformis
364. Clinical pharmacokinetics of dapsone